If you have any question, please feel free to email us. We will touch with you as soon as possible.
CAS:154229-18-2
Source:India
Qualifications:USDMF/-/-/-/-
| Name | Abiraterone Acetate |
|---|---|
| Chinese name | 醋酸阿比特龙 |
| Cas Number | 154229-18-2 |
| Source | India |
| Qualifications | USDMF/-/-/-/- |
Abiraterone is an orally effective CYP17A enzyme irreversible inhibitor developed by Johnson & Johnson in the United States. On April 28, 2011, the FDA approved its combination with prednisone for the treatment of advanced castration-resistant prostate cancer patients with a history of docetaxel treatment. It is another breakthrough in the treatment of castration-resistant prostate cancer after the cabazitax match. Clinical studies have shown that abiraterone acetate can significantly reduce the level of prostate specific antigen (PSA) in patients with prostate cancer, and help shrink tumors and extend the life of patients with advanced prostate cancer by several years. Abiraterone was recognized soon after it went public, and its global sales grew rapidly, making it another blockbuster drug for Johnson & Johnson.
Hot Tags: abiraterone acetate api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Clofarabine API, Oseltamivir Phosphate API, Deoxycholic Acid API, Vardenafil API, Active Pharmaceutical Ingredient, Ulipristal Acetate API
Tel:+86-020-61855200-902
Fax:+86-020-66392525
Email:info@upharm.cn
Address:12th floor, No. 181, Kexue Avenue, Huangpu District, Guangzhou, China
